Article Information
History
- November 13, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Lidia Staszewsky1,□,*,
- Jennifer Meessen1,□,
- Deborah Novelli1,
- Ulla Wienhues-Thelen2,
- Marcello Disertori3,
- Aldo P Maggioni4,
- Serge Masson1,
- Gianni Tognoni1,
- Maria Grazia Franzosi1,
- Donata Lucci4,
- Roberto Latini1,
- GISSI-AF Investigators.
- 1Department of Cardiovascular Medicine, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
- 2Roche Diagnostics GmbH, Penzberg, Germany
- 3Healthcare Research and Innovation Program, IRCS-HTA, BK Foundation, Trento, Italy
- 4ANMCO Research Center, Florence, Italy
- ↵*Corresponding author: Dr. Lidia Staszewsky, Department of Cardiovascular Medicine, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Via Mario Negri 2, 20156, Milan, Italy, Tel: +39 0239014508, e-mail: lidia.staszewsky{at}marionegri.it
↵□ equally contributed to data analysis and interpretation.
Posted November 13, 2020.
Total NT-proBNP, a novel biomarker in atrial fibrillation. A mechanistic analysis of the GISSI-AF trial
